Dina Chaya Director

Dina is a partner with NeoMed Management, and Advisor to Omega Funds. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel, and Wilson Therapeutics. Dina serves on the Board of Directors of Imago BioSciences and Spruce Biosciences as well as Oxular, plus is a member of the Venture Capital Platform Council of Invest Europe. Dina is a CFA charter holder and holds a PhD in molecular and cellular biology from Paris VI University, France.

Scroll to Top